Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02065466 | Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases | withdrawn | Phase 1 / Phase 2 | 0 | University of ArizonaOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT02452281 | Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Rabih SaidOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT01764009 |
| Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma(AIMM) |
| withdrawn |
| Phase 1 / Phase 2 |
| 0 |
| Valerio TherapeuticsINDUSTRY |
| 2 |
| Sep 11, 2015 |
| clinicaltrials |
| NCT01851408 | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 15, 2015 | clinicaltrials |
| NCT01531244 | Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 18, 2014 | clinicaltrials |
| NCT01689870 | Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Ludwig Institute for Cancer ResearchOTHER | 0 | Apr 1, 2014 | clinicaltrials |
| NCT01933061 | Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma | withdrawn | Phase 2 | 0 | Celgene CorporationINDUSTRY | 0 | Feb 4, 2014 | clinicaltrials |
| NCT00357461 | Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 0 | May 15, 2013 | clinicaltrials |
| NCT01340729 | Open-Label Study of TPI 287 for Patients With Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT01416844 | Study of Immune Responses in Patients With Metastatic Melanoma | withdrawn | Phase 2 | 0 | Providence Health & ServicesOTHER | 1 | Mar 7, 2013 | clinicaltrials |
| NCT01216787 | RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00085579 | Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 12, 2012 | clinicaltrials |
| NCT01409187 | IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 26, 2012 | clinicaltrials |
| NCT00963664 | Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma | withdrawn | Phase 2 | 250 | NeoPlas InnovationOTHER | 1 | Sep 9, 2009 | clinicaltrials |
Data updated 23 days agoSource updated Apr 21, 2016source: clinicaltrials